Skip to content
OpenCapital
Get started

Prime Medicine PRME Market capitalization

Market capitalization at other companies

Eli Lilly logo
Eli LillyLLY
$821.68B+10.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$113.44B-8.9%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$1.51B+106%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$4.57B+56.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.43B+24.5%
Regenxbio logo
RegenxbioRGNX
$432.52M+20.8%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%—

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Computed from the period-end share price: $628.32M.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's market capitalization?
Prime Medicine (PRME) reported market capitalization of $628.32M in Q1 2026.
How has Prime Medicine's market capitalization changed year-over-year?
Prime Medicine's market capitalization increased by 140.7% year-over-year, from $261.01M to $628.32M.
What is the long-term trend for Prime Medicine's market capitalization?
Over 3 years (2022 to 2025), Prime Medicine's market capitalization has grown at a -23.1% compound annual growth rate (CAGR), from $1.38B to $626.37M.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.